Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also off… Read more
Sensei Biotherapeutics Inc (SNSE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.156x
Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) has a cash flow conversion efficiency ratio of -0.156x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.59 Million) by net assets ($23.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sensei Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Sensei Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sensei Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sensei Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Strategic Metals Ltd
PINK:SMDZF
|
-0.002x |
|
Borealis Exploration Ltd
PINK:BOREF
|
0.000x |
|
Almadex Minerals Ltd
PINK:AAMMF
|
-0.007x |
|
Sena J Property PCL
BK:SENX
|
-0.017x |
|
INSPIRATION HEA.GR.LS-10
F:LXD1
|
N/A |
|
Luna Innovations Incorporated
NASDAQ:LUNA
|
0.025x |
|
FREEPORT RES
F:4XH
|
N/A |
|
Avant Technologies Inc.
OTCQB:AVAI
|
0.124x |
Annual Cash Flow Conversion Efficiency for Sensei Biotherapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Sensei Biotherapeutics Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $38.39 Million | $-24.67 Million | -0.643x | -30.24% |
| 2023-12-31 | $64.89 Million | $-32.02 Million | -0.493x | -30.75% |
| 2022-12-31 | $103.41 Million | $-39.03 Million | -0.377x | -82.74% |
| 2021-12-31 | $146.51 Million | $-30.26 Million | -0.207x | +81.46% |
| 2020-12-31 | $15.89 Million | $-17.70 Million | -1.114x | -992.43% |
| 2019-12-31 | $-68.66 Million | $-8.57 Million | 0.125x | -35.27% |
| 2018-12-31 | $-53.48 Million | $-10.31 Million | 0.193x | -- |